Get the Stockscreener App
14.80
4.61%
-0.715
Gh Research Plc stock is traded at $14.80, with a volume of 58,641.
It is down -4.61% in the last 24 hours and up +0.71% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$15.52
Open:
$15.68
24h Volume:
58,641
Relative Volume:
0.16
Market Cap:
$918.35M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-18.74
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-7.06%
1M Performance:
+0.71%
6M Performance:
+23.99%
1Y Performance:
+36.08%
1-Day Range:
$14.65
$15.93
1-Week Range:
$14.65
$16.48
52-Week Range:
$7.98
$19.51
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
14.80 | 962.70M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.79 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 - Seeking Alpha
Guggenheim raises GH Research stock price target to $34 on trial data - Investing.com Australia
GH Research reports Phase 2b trial results for depression treatment - Investing.com Nigeria
Activity Recap: Does GH Research PLC stock benefit from AI growthQuarterly Profit Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
(GHRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aug Ideas: Can GH Research PLC ride the EV waveJuly 2025 Closing Moves & Weekly Market Pulse Updates - baoquankhu1.vn
Market Catalysts: Is GH Research PLC stock undervalued right nowJuly 2025 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
HC Wainwright Forecasts Reduced Earnings for GH Research - Defense World
Citizens raises GH Research stock price target on phase 3 progress - Investing.com India
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat
Needham raises GH Research stock price target to $32 on phase 3 plans - Investing.com Australia
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
GH Research (NASDAQ:GHRS) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
FY2025 EPS Estimates for GH Research Cut by HC Wainwright - MarketBeat
GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone - TipRanks
GH Research Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
GH Research reports Phase 2b trial results for depression treatment By Investing.com - Investing.com UK
GH Research (Nasdaq: GHRS) posts 2025 loss, touts strong Phase 2b TRD data - Stock Titan
Brokers Offer Predictions for GH Research FY2030 Earnings - Defense World
Analysts Issue Forecasts for GH Research FY2030 Earnings - MarketBeat
Entry Recap: Is GH Research PLC stock undervalued right now2025 Stock Rankings & Daily Profit Focused Stock Screening - baoquankhu1.vn
GH Research (NASDAQ:GHRS) Price Target Raised to $70.00 at HC Wainwright - MarketBeat
How (GHRS) Movements Inform Risk Allocation Models - Stock Traders Daily
Aug Outlook: Should you buy the dip on HTLM2025 Trading Recap & Verified Entry Point Signals - baoquankhu1.vn
Surprises Report: Is GH Research PLC showing insider buyingJuly 2025 Analyst Calls & Expert-Curated Trade Recommendations - baoquankhu1.vn
GH Research PLC (NASDAQ:GHRS) Receives $34.11 Consensus Price Target from Brokerages - Defense World
Is GH Research PLC (1KA) stock at risk of policy regulationJuly 2025 Analyst Calls & Weekly High Conviction Ideas - mfd.ru
GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CenterBook Partners LP Invests $2.38 Million in GH Research PLC $GHRS - MarketBeat
GH Research PLC (GHRS) Stock Analysis: Exploring a Promising 113.5% Upside in the Biotech Arena - DirectorsTalk Interviews
Stock Report: Is DBRG stock trending bullishJuly 2025 Analyst Calls & Consistent Profit Alerts - baoquankhu1.vn
GH Research (GHRS) Projected to Post Earnings on Thursday - MarketBeat
RBC Capital Cite GH Research PLC's (GHRS) Long-Term Sales Potential Following Psychedelics Symposium - Finviz
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics Symposium - Insider Monkey
GH Research PLC Reports Q3 2025 Financial Results - MSN
GH Research (NASDAQ:GHRS) Shares Up 8.8%Should You Buy? - MarketBeat
Trading Systems Reacting to (GHRS) Volatility - Stock Traders Daily
Is GH Research PLC stock forming a cup and handleJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - mfd.ru
GH Research PLC (GHRS) Stock Analysis: Potential Upside of 124.74% and Strong Buy Ratings - DirectorsTalk Interviews
Can GH Research PLC ride the EV waveJuly 2025 Summary & Long-Term Investment Growth Plans - mfd.ru
Fed Meeting: Is GH Research PLC stock forming a cup and handle2025 Major Catalysts & High Conviction Investment Ideas - baoquankhu1.vn
Price Action: Is Vitesse Energy Inc stock technically oversoldJuly 2025 Snapshot & Capital Efficiency Focused Ideas - baoquankhu1.vn
How Gh Research Plc (GHRS) Affects Rotational Strategy Timing - Stock Traders Daily
GH Research stock soars after IND update announcement By Investing.com - Investing.com Nigeria
Dividend Watch: What is the dividend yield of GH Research PLC2025 Volatility Report & Daily Stock Trend Reports - baoquankhu1.vn
GH Research PLC (GHRS) Stock Analysis: A Biotech Gem With Over 100% Upside Potential - DirectorsTalk Interviews
Market Review: Can GH Research PLC ride the EV waveQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Market Pulse: Is GH Research PLC a turnaround storyJuly 2025 Price Swings & Consistent Income Trade Recommendations - baoquankhu1.vn
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):